Hyliion and ARS Pharmaceuticals Face Securities Fraud Investigations

Key Facts

Amid intensifying legal scrutiny over emerging players in the biotech and sustainable transport sectors, law firm Levi & Korsinsky has initiated investigations into potential securities fraud involving Hyliion Holdings and ARS Pharmaceuticals. According to reports, Hyliion's stock faced significant selling pressure, dropping up to 17% following a research report that questioned the credibility of a $133 million deal. Simultaneously, ARS Pharmaceuticals saw its shares tumble by over 23% after its flagship drug, Neffy, failed to secure critical new commercial formulary coverage.

These investigations compound existing shareholder concerns, as the allegations against Hyliion stem from a Pelican Way Research report challenging the legitimacy of major business partnerships—a narrative reminiscent of past volatility in the EV trucking space. For ARS Pharmaceuticals, the setback in insurance coverage projections directly threatens future revenue streams, as Neffy is a central component of its therapeutic portfolio. Per market data, these sharp declines underscore the high sensitivity of retail investors to short-seller reports and regulatory hurdles in the healthcare industry.

Looking ahead, traders are monitoring technical support levels for both firms following the recent volatility, though updated closing prices remain unavailable. As legal proceedings evolve, the companies may be forced to issue formal rebuttals or face class-action lawsuits that could impact their balance sheets. While no direct corporate catalysts are listed in the immediate calendar, broader sector sentiment may be influenced by upcoming macro data, including the US CB Consumer Confidence report, which previously printed at 91.2 per data from June 30, 2026.